EU promotes lung research at the Max Planck Institute in Bad Nauheim
Soni Savai Pullamsetti Receives 2 Million Euro Research Grant from the European Research Council.
Menu
close
Soni Savai Pullamsetti Receives 2 Million Euro Research Grant from the European Research Council.
26 participants learnt how to communicate their research effectively to different target audiences and developed potential outreach activities at DZG workshop for early career scientists.
The 9th DZL Annual Meeting took place on January 23 and 24, 2020 in Lübeck-Travemünde, bringing together around 500 scientists, physicians, and junior researchers from five sites.
The German Center for Lung Research (DZL) was honored with the Balzan Prize for exceptional achievements on November 15th in Bern. The prize is worth 750 000 Swiss Francs.
Six selected DZL early career scientists improved their writing skills and gained insight into the successful publication process.
In collaboration with an international team, DZL scientists from Research Center Borstel developed and tested a new antibody which might be used against inflammatory diseases.
MicroRNAs, also called miRNAs or miR, play an important role in cell communication and affect gene activity in various ways.
Is computed tomography suitable for detecting lung cancer at a very early stage and thus still well treatable? Scientists at the German Cancer Research Center have investigated this with the LUSI study started in 2007.
ERS, the European Respiratory Society, is the world's largest consortium of pulmonary experts, along with its US affiliate ATS. In September 2018, Prof. Dr. Tobias Welte, Clinic Director of Pulmonology of the Hannover Medical School...
Although research is advancing with great strides, the life expectancy of people with cystic fibrosis (CF) is still significantly reduced.
Prematurely born infants often develop a chronic lung disease known as Bronchopulmonary Dysplasia (BPD). To date, it has only been possible to diagnose the condition based on clinical symptoms and with little differentiation.
Pulmonary Arterial Hypertension (PAH) is a progressive, fatal disease of the pulmonary vasculature. Affected patients have a poor prognosis, and treatment options are limited.
